Table 1.
Baseline clinical and angiographic characteristics of patients in ACS and CCS groups
| Characteristics | All (n = 320) | ACS (n = 139) | CCS (n = 181) | P value |
|---|---|---|---|---|
| Male, n (%) | 249 (77.8%) | 121 (87.1%) | 128 (70.7%) | < 0.001 |
| Age, years, mean ± SD | 59.70 ± 10.45 | 58.99 ± 11.88 | 60.25 ± 9.21 | 0.283 |
| Medical history, n (%) | ||||
| Atrial fibrillation | 11 (3.4%) | 10 (7.2%) | 1 (0.6%) | 0.001 |
| Hypertension | 166 (51.9%) | 79 (56.8%) | 87 (48.1%) | 0.120 |
| Diabetes mellitus | 80 (25.0%) | 32 (23.0%) | 48 (26.5%) | 0.474 |
| ASCVD | 148 (46.3%) | 60 (43.2%) | 88 (48.6%) | 0.332 |
| Prior PCI | 65 (20.3%) | 30 (21.6%) | 35 (19.3%) | 0.621 |
| Stroke | 19 (5.9%) | 10 (7.2%) | 9 (5.0%) | 0.404 |
| Alcohol drinking | 50 (15.6%) | 28 (20.1%) | 22 (12.2%) | 0.051 |
| Smoking | 141 (44.1%) | 71 (51.1%) | 70 (38.7%) | 0.027 |
| Smoking years | 12.90 ± 15.94 | 15.14 ± 16.36 | 11.17 ± 15.43 | 0.027 |
| Laboratory results, mean ± SD | ||||
| WBC, × 109/L | 7.00 ± 2.36 | 7.89 ± 2.84 | 6.32 ± 1.63 | < 0.001 |
| Hb, g/L | 140.76 ± 17.51 | 138.63 ± 19.88 | 142.39 ± 15.30 | 0.057 |
| HbA1c, % | 6.48 ± 1.70 | 6.43 ± 1.76 | 6.52 ± 1.65 | 0.671 |
| NT-proBNP, pg/ml | 670.25 ± 1906.92 | 1345.28 ± 2727.79 | 147.76 ± 296.54 | < 0.001 |
| Hs-cTnI, pg/ml | 292.11 ± 978.31 | 631.49 ± 1376.67 | 7.93 ± 2.82 | < 0.001 |
| CK-MB, U/L | 25.74 ± 35.65 | 37.86 ± 44.50 | 16.40 ± 23.04 | < 0.001 |
| Glucose, mmol/L | 6.15 ± 2.40 | 6.39 ± 2.91 | 5.98 ± 1.99 | 0.266 |
| Creatine, μmol/L | 77.10 ± 80.41 | 91.36 ± 119.68 | 66.15 ± 14.16 | 0.005 |
| eGFR, ml/min/1.73m2 | 104.43 ± 28.09 | 102.07 ± 33.01 | 106.24 ± 23.57 | 0.188 |
| Uric acid, μmol/L | 312.55 ± 80.69 | 332.93 ± 83.66 | 297.46 ± 75.18 | < 0.001 |
| TC, mmol/L | 3.79 ± 0.99 | 3.95 ± 1.01 | 3.68 ± 0.95 | 0.016 |
| TG, mmol/L | 1.71 ± 1.35 | 1.85 ± 1.55 | 1.61 ± 1.17 | 0.116 |
| HDL-C, mmol/L | 1.06 ± 0.26 | 1.02 ± 0.24 | 1.08 ± 0.26 | 0.023 |
| LDL-C, mmol/L | 2.23 ± 0.84 | 2.42 ± 0.87 | 2.09 ± 0.80 | < 0.001 |
| VLDL-C, mmol/L | 0.52 ± 0.47 | 0.53 ± 0.51 | 0.51 ± 0.45 | 0.663 |
| Apo A1, g/L | 1.25 ± 0.26 | 1.20 ± 0.23 | 1.29 ± 0.27 | 0.001 |
| Apo B, g/L | 0.84 ± 0.25 | 0.89 ± 0.27 | 0.81 ± 0.23 | 0.003 |
| Apo B/A1 | 0.70 ± 0.25 | 0.77 ± 0.28 | 0.64 ± 0.22 | < 0.001 |
| Lipoprotein (a), mg/dl | 23.24 ± 28.42 | 25.05 ± 28.99 | 21.84 ± 27.98 | 0.319 |
| TSH, μIU/ml | 3.51 ± 5.12 | 3.25 ± 5.09 | 3.71 ± 5.15 | 0.439 |
| D-dimer, μg/ml | 564.49 ± 1354.78 | 749.41 ± 1765.73 | 422.49 ± 903.22 | 0.032 |
| LVEF, % | 62.82 ± 7.81 | 60.77 ± 7.76 | 64.50 ± 7.46 | < 0.001 |
| Culprit vessels, n (%) | ||||
| LAD | 191 (59.7%) | 70 (50.4%) | 121 (66.9%) | |
| LCX | 40 (12.5%) | 20 (14.4%) | 20 (11.0%) | |
| RCA | 56 (17.5%) | 32 (23.0%) | 24 (13.3%) | |
| Lesion site, n (%) | ||||
| Proximal | 165 (51.6%) | 72 (51.8%) | 93 (51.4%) | |
| Middle | 109 (34.1%) | 41 (29.5%) | 68 (37.6%) | |
| Distal | 13 (4.1%) | 9 (6.5%) | 4 (2.2%) | |
| Stents, n (%) | ||||
| 0 | 95 (29.7%) | 28 (20.1%) | 67 (37.0%) | |
| 1 | 124 (38.8%) | 55 (39.6%) | 69 (38.1%) | |
| 2 | 67 (20.9%) | 30 (21.6%) | 37 (20.4%) | |
| 3 | 21 (6.6%) | 16 (11.5%) | 5 (2.8%) | |
| > 3 | 13 (4.1%) | 10 (7.2%) | 3 (1.7%) | |
| Statins, n (%) | 208 (65.0%) | 93 (66.9%) | 115 (63.5%) | 0.531 |
ACS acute coronary syndrome, CCS chronic coronary syndrome, ASCVD atherosclerotic cardiovascular disease, PCI percutaneous coronary intervention, SD standard deviation, WBC white blood cell, Hb hemoglobin, HbA1c glycosylated hemoglobin, NT-proBNP N-terminal B-type natriuretic peptide, Hs-cTnI high-sensitivity cardiac troponin I, CK-MB creatine kinase-MB, eGFR estimated glomerular filtration rate, TC total cholesterol, TG total triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, VLDL-C very low-density lipoprotein cholesterol, Apo apolipoprotein, TSH thyroid stimulating hormone, LVEF left ventricular ejection fraction, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery